Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Earnings for Aprea Therapeutics, Inc. (APRE)
Earnings in 2023 (TTM): $-14,286,756
According to Aprea Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-14,286,756. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Aprea Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-14,286,756 | $-14,286,756 |
| 2022 | $-112,662,027 | $-224,875,387 |
| 2021 | $-37,127,303 | $-36,536,576 |
| 2020 | $-53,478,812 | $-53,916,802 |
| 2019 | $-28,059,807 | $-26,405,062 |
| 2018 | $-15,528,269 | $-15,528,269 |
| 2017 | $-15,190,250 | $-15,190,250 |